Rhythm Pharmaceuticals Nears Key FDA Calls With Global Growth Potential

Simply Wall St.

Yesterday

Rhythm Pharmaceuticals is moving toward a key FDA decision for IMCIVREE in acquired hypothalamic obesity, with preparations underway for a potential U.S. approval and commercial launch. The company ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2616066228"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616066228\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616066228?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-02 09:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616066228","market":"sg","top_or_hot":-1,"title":"Rhythm Pharmaceuticals Nears Key FDA Calls With Global Growth Potential","media":"Simply Wall St.","content":"<div>\n<p>Rhythm Pharmaceuticals is moving toward a key FDA decision for IMCIVREE in acquired hypothalamic obesity, with preparations underway for a potential U.S. approval and commercial launch. The company ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-nears-key-fda-calls-with-global-growt\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rhythm Pharmaceuticals Nears Key FDA Calls With Global Growth Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRhythm Pharmaceuticals Nears Key FDA Calls With Global Growth Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-02 09:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-nears-key-fda-calls-with-global-growt><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Rhythm Pharmaceuticals is moving toward a key FDA decision for IMCIVREE in acquired hypothalamic obesity, with preparations underway for a potential U.S. approval and commercial launch. The company ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-nears-key-fda-calls-with-global-growt\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RYTM","symbol_name":"Rhythm Pharmaceuticals Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-nears-key-fda-calls-with-global-growt","article_id":"2616066228","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-nears-key-fda-calls-with-global-growt","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616066228","pubTimestamp":1772414695,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Rhythm Pharmaceuticals is moving toward a key FDA decision for IMCIVREE in acquired hypothalamic obesity, with preparations underway for a potential U.S. approval and commercial launch.\nThe company has received constructive FDA feedback at its end of Phase 2 meeting for oral candidate bivamelagon, supporting plans to progress into Phase 3.\nRhythm is also working on broader commercial access, reimbursement, and geographic expansion in Europe and Japan for its rare neuroendocrine disease...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"RYTM":"Rhythm Pharmaceuticals Inc.","BK4139":"生物科技","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Rhythm Pharmaceuticals接近FDA关键评级，具有全球增长潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RYTM":0.9},"content_text":"Rhythm Pharmaceuticals is moving toward a key FDA decision for IMCIVREE in acquired hypothalamic obesity, with preparations underway for a potential U.S. approval and commercial launch. The company has received constructive FDA feedback at its end of Phase 2 meeting for oral candidate bivamelagon, supporting plans to progress into Phase 3. Rhythm is also working on broader commercial access, reimbursement, and geographic expansion in Europe and Japan for its rare neuroendocrine disease portfolio.  Rhythm Pharmaceuticals, ticker NasdaqGM:RYTM, is drawing attention as it approaches a pivotal regulatory point while its shares trade around $92.73. The stock has seen a very large gain over three years and a 68.9% return over the past year, even as it has recorded a 11.7% decline year to date. That mix of strong multi year performance and recent pullback is the backdrop for investors weighing the impact of upcoming catalysts. With a late stage filing for IMCIVREE in acquired hypothalamic obesity and Phase 3 planning for bivamelagon, Rhythm is concentrating on rare neuroendocrine conditions with few treatment options. At the same time, efforts to broaden reimbursement and extend its reach in Europe and Japan could influence how any approved therapies translate into real world adoption and revenue. Investors are likely to focus on the timing and outcomes of regulatory decisions alongside execution on global access. Stay updated on the most important news stories for Rhythm Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Rhythm Pharmaceuticals. NasdaqGM:RYTM Earnings & Revenue Growth as at Mar 2026 📰 Beyond the headline: 0 risks and 3 things going right for Rhythm Pharmaceuticals that every investor should see. AdvertisementQuick Assessment  ✅ Price vs Analyst Target: At US$92.73, Rhythm trades about 34% below the US$140.67 analyst price target range midpoint. ✅ Simply Wall St Valuation: The shares are described as trading at roughly 78.5% below an estimated fair value. ❌ Recent Momentum: The stock has a 30 day return of about a 9.5% decline.  There is only one way to know the right time to buy, sell or hold Rhythm Pharmaceuticals. Head to Simply Wall St's\ncompany report for the latest analysis of Rhythm Pharmaceuticals's fair value. Key Considerations  📊 The late stage IMCIVREE and bivamelagon programs, alongside expansion in Europe and Japan, put upcoming regulatory and launch execution at the center of the story. 📊 Keep an eye on FDA decisions, timing of any label expansions, and how quickly revenue of US$189.8m changes as new indications and regions come online. ⚠️ With a net loss of US$201.9m and a P/E of around 31 on negative earnings, funding needs and cash burn remain important to track against clinical and commercial milestones.  Dig Deeper For the full picture including more risks and rewards, check out the\ncomplete Rhythm Pharmaceuticals analysis. Alternatively, you can check out the\ncommunity page for Rhythm Pharmaceuticals to see how other investors believe this latest news will impact the company's narrative.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}